Moleculin Biotech (MBRX) Set to Release Quarterly Earnings on Thursday

Moleculin Biotech (NASDAQ:MBRX) is projected to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Moleculin Biotech to post earnings of ($8.87) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($28.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($31.00) by $3.00. On average, analysts expect Moleculin Biotech to post ($47.40) EPS for the current fiscal year and ($23.10) EPS for the next fiscal year.

Moleculin Biotech Trading Down 6.9%

MBRX stock opened at $8.06 on Wednesday. Moleculin Biotech has a 12 month low of $3.23 and a 12 month high of $253.05. The firm has a 50-day moving average of $10.27 and a two-hundred day moving average of $37.96.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on MBRX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Thursday, October 15th. HC Wainwright reduced their price objective on Moleculin Biotech to $60.00 and set a “buy” rating on the stock in a research report on Friday, August 28th. Finally, Wall Street Zen lowered Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $60.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression. Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.